Home Contact Center Add this

12 October 2017 / international

GenePOC Launches its new GenePOC™ GBS DS test [Read more]

03 October 2017 / international

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP) [Read more]

29 September 2017 / international

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award [Read more]


15 June 2017

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN [Read more]

01 June 2017

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284 [Read more]

09 March 2017

Debiopharm International SA Appeals to the Supreme Court regarding Towa Pharmaceutical Co., Ltd. case [Read more]


13 September 2017

Debiopharm Investment acquires minority stake in Les Toises clinics, Switzerland [Read more]

12 September 2017

Le professeur Peter Vogel nommé titulaire de la nouvelle chaire Debiopharm de philanthropie familiale à l’IMD [Read more]

27 June 2017

Challenge Debiopharm-Inartis récompense les six finalistes 2017 [Read more]


01 December 2016

Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient Stratification [Read more]

29 October 2016

Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I [Read more]

29 October 2016

The Staphylococcal-specific Antibiotic Debio 1450 Minimizes Disturbance to the Gut Microbiota in Mice [Read more]


bulle slideshow group

bulle slideshow diagnostics

bulle slideshow international

bulle slideshow investment

bulle slideshow research